Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPM1 | P06748 | 1/20 | 0.31 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.31 |
| ▸ | CLK1 | P49759 | 1/20 | 0.30 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29041967 | 0.88 | IRAK4 (0.43) | TLR8MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL20502284 | 0.88 | BACE1 (0.35) | BACE1MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL30676504 | 0.86 | IRAK4 (0.36) | TLR8BACE1MAPTNPC1RAB9A | |
| SCHEMBL11890643 | 0.85 | TLR8 (0.44) | TLR8BACE1MAPTNPC1RAB9A | |
| SCHEMBL30122249 | 0.85 | IRAK4 (0.41) | TLR8MAPTALDH1A1HTTIRAK4 | |
| SCHEMBL29083592 | 0.83 | TLR8 (0.37) | TLR8BACE1MAPTNPC1RAB9A | |
| SCHEMBL25338707 | 0.81 | TLR8 (0.38) | TLR8BACE1MAPTNPC1RAB9A | |
| SCHEMBL15345154 | 0.81 | TLR8 (0.39) | TLR8BACE1MAPTNPC1RAB9A | |
| SCHEMBL29141445 | 0.81 | TLR8 (0.36) | TLR8IRAK4PTPN11 | |
| SCHEMBL27007121 | 0.80 | TLR8 (0.41) | TLR8BACE1MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3596051-B1 | FUSED BICYCLIC COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD (IN) | 2022-04-27 | — | — | EP | disclosed |
| EP-3596051-B1 | FUSED BICYCLIC COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD (IN) | 2022-04-27 | — | — | EP | disclosed |
| US-20200087281-A1 | FUSED BICYCLIC COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LIMITED (IN) | 2020-03-19 | — | — | US | disclosed |
| US-20200087281-A1 | FUSED BICYCLIC COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LIMITED (IN) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087281-A1 | FUSED BICYCLIC COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | GPR119, GPR65, GPR88 | TLR8 410/4885BACE1 656/4885MAPT 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.